Immunosuppressive role of extracellular vesicles: HLA-G, an important player

Grange, Cristina; Camussi, Giovanni

doi:10.21037/atm.2017.03.61

Cited by 9 publications

(4 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The molecular content of tumor-derived EVs includes a broad variety of proteins, lipids, glycans, and RNA species, and partly resembles the content of their parental cell (Figure 1) [38,39]. Furthermore, tumor-derived EVs may contain immunoinhibitory ligands and immunostimulatory molecules [40,41]. Malignant transformation is associated with increased EV release [38,42,43].…”

Section: Lcevs and Lmementioning

confidence: 99%

Extracellular Vesicles: New Players in Lymphomas

Navarro-Tableros

Gomez

Camussi

et al. 2018

IJMS

Self Cite

View full text Add to dashboard Cite

Lymphomas are heterogeneous diseases, and the term includes a number of histological subtypes that are characterized by different clinical behavior and molecular phenotypes. Valuable information on the presence of lymphoma cell-derived extracellular vesicles (LCEVs) in the bloodstream of patients suffering from this hematological cancer has recently been provided. In particular, it has been reported that the number and phenotype of LCEVs can both change as the disease progresses, as well as after treatment. Moreover, the role that LCEVs play in driving tumor immune escape has been reported. This makes LCEVs potential novel clinical tools for diagnosis, disease progression, and chemoresistance. LCEVs express surface markers and convey specific molecules in accordance with their cell of origin, which can be used as targets and thus lead to the development of specific therapeutics. This may be particularly relevant since circulating LCEVs are known to save lymphoma cells from anti-cluster of differentiation (CD)20-induced complement-dependent cytotoxicity. Therefore, effort should be directed toward investigating the feasibility of using LCEVs as predictive biomarkers of disease progression and/or response to treatment that can be translated to clinical use. The use of liquid biopsies in combination with serum EV quantification and cargo analysis have been also considered as potential approaches that can be pursued in the future. Upcoming research will also focus on the identification of specific molecular targets in order to generate vaccines and/or antibodies against LCEVs. Finally, the removal of circulating LCEVs has been proposed as a simple and non-invasive treatment approach. We herein provide an overview of the role of LCEVs in lymphoma diagnosis, immune tolerance, and drug resistance. In addition, alternative protocols that utilize LCEVs as therapeutic targets are discussed.

show abstract

Section: Lcevs and Lmementioning

confidence: 99%

Extracellular Vesicles: New Players in Lymphomas

Navarro-Tableros

Gomez

Camussi

et al. 2018

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…The membrane-bound HLA-G protein is selectively expressed in placental extraphobic trophoblast cells, fetal endothelial cells, macrophages of the chorionic villus mesenchyme, and epithelial cells of the thymus medulla 18,19,22,26 . However, low levels of HLA-G gene transcription have been detected in some adult tissue cells, such as T and B lymphocytes.…”

Section: Introductionmentioning

confidence: 99%

Asociación del polimorfismo genético del locus HLA-G y la susceptibilidad a contraer lupus eritematoso sistémico expresada en algunas manifestaciones clínicas

Guerra-Monrroy

Sosa-Tordoya

2020

J. Selva Andina Res. Soc.

View full text Add to dashboard Cite

La susceptibilidad individual en autoinmunidad puede estar determinada por una combinación de polimorfismos específicos de genes que codifican para múltiples proteínas, citoquinas, antígenos del complejo principal de histocompatibilidad, moléculas de adhesión, y proteínas celulares. Esta condición puede conducir a la expresión anormal de moléculas inmunoreguladoras y finalmente resultar en el desarrollo o exacerbación de la enfermedad autoinmune. HLA-G es una molécula glicoprotéica del MHC de clase I, la cual cumple con funciones muy importante al momento de activar y regular el sistema inmune. Por lo tanto, lo que se pretende con este estudio es determinar la asociación genética entre el polimorfismo de 14 pb del gen HLA-G con la susceptibilidad a contraer LES y las manifestaciones clínicas de la enfermedad. La población de estudio consistió de 120 pacientes con LES y 112 pacientes sin la enfermedad (grupo control), 94% procedía de la ciudad de La Paz, quienes asistieron al Instituto SELADIS. Para el estudio se obtuvo el DNA humano a partir de sangre periférica, se realizó la PCR para la tipificación molecular de los genotipos y alelos que fueron revelados por medio de electroforesis en gel de agarosa. Al mismo tiempo se realizaron pruebas serológicas por ELISA para determinar la presencia de anticuerpos IgG anti-DNA de doble cadena en los pacientes lúpicos. Los resultados de la PCR mostraron que los pacientes lúpicos tienen mayor frecuencia de expresión del genotipo Ins/Del (OR=1.72, p<0.05); mientras que, la presencia del genotipo homocigoto Ins/Ins es más frecuente en el grupo control (OR=0.29, p<0.001), mostrándose de esta forma que el primer genotipo es un factor de riesgo y el segundo, un factor de protección a padecer LES respectivamente. Se observó también que entre pacientes y controles no existe diferencia significativa en la frecuencia de presentación del genotipo Del/Del en homocigosis. En cuanto a las frecuencias alélicas se obtuvo que el alelo deleción en más frecuente en el grupo de pacientes lúpicos, a comparación del grupo control donde ambos alelos presentaron el mismo porcentaje. Con respecto a las manifestaciones clínicas se observó que el polimorfismo Ins/Del (O.R=8.64) es factor de riesgo para el desarrollo de manifestaciones dermatológicas. 2020. Journal of the Selva Andina Research Society®. Bolivia. Todos los derechos reservados.

show abstract

“…EVs have important effects on innate and adaptive IS cells, participating both in the presentation of antigens and activation of the IS as well as in its modulation and suppression [123]. For example, placental cells are important in the tolerization of the IS during foetal development thanks to the secretion of EVs containing human leukocyte antigen G (HLA-G) [124]. In turn, in vitro studies have shown how immune cells tolerated by this mechanism can do the same, thus facilitating the tolerization of all cells [125].…”

Section: Importance Of Cell Trafficking and Evs In Immune-mediated In...mentioning

confidence: 99%

An Updated View of the Importance of Vesicular Trafficking and Transport and Their Role in Immune-Mediated Diseases: Potential Therapeutic Interventions

et al. 2022

View full text Add to dashboard Cite

Cellular trafficking is the set of processes of distributing different macromolecules by the cell. This process is highly regulated in cells, involving a system of organelles (endomembranous system), among which are a great variety of vesicles that can be secreted from the cell, giving rise to different types of extracellular vesicles (EVs) that can be captured by other cells to modulate their function. The cells of the immune system are especially sensitive to this cellular traffic, producing and releasing different classes of EVs, especially in disease states. There is growing interest in this field due to the therapeutic and translational possibilities it offers. Different ways of taking advantage of the understanding of cell trafficking and EVs are being investigated, and their use as biomarkers or therapeutic targets is being investigated. The objective of this review is to collect the latest results and knowledge in this area with a specific focus on immune-mediated diseases. Although some promising results have been obtained, further knowledge is still needed, at both the basic and translational levels, to understand and modulate cellular traffic and EVs for better clinical management of these patients.

show abstract

Immunosuppressive role of extracellular vesicles: HLA-G, an important player

Cited by 9 publications

References 18 publications

Extracellular Vesicles: New Players in Lymphomas

Extracellular Vesicles: New Players in Lymphomas

Asociación del polimorfismo genético del locus HLA-G y la susceptibilidad a contraer lupus eritematoso sistémico expresada en algunas manifestaciones clínicas

An Updated View of the Importance of Vesicular Trafficking and Transport and Their Role in Immune-Mediated Diseases: Potential Therapeutic Interventions

Contact Info

Product

Resources

About